SG164279A1 - Tricyclic thrombin receptor antagonists - Google Patents
Tricyclic thrombin receptor antagonistsInfo
- Publication number
- SG164279A1 SG164279A1 SG200607217-7A SG2006072177A SG164279A1 SG 164279 A1 SG164279 A1 SG 164279A1 SG 2006072177 A SG2006072177 A SG 2006072177A SG 164279 A1 SG164279 A1 SG 164279A1
- Authority
- SG
- Singapore
- Prior art keywords
- substituted
- bond
- receptor antagonists
- optionally substituted
- thrombin receptor
- Prior art date
Links
- 239000003856 thrombin receptor antagonist Substances 0.000 title 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 125000004419 alkynylene group Chemical group 0.000 abstract 1
- 206010003119 arrhythmia Diseases 0.000 abstract 1
- 230000006793 arrhythmia Effects 0.000 abstract 1
- 229940125692 cardiovascular agent Drugs 0.000 abstract 1
- 239000002327 cardiovascular agent Substances 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 201000010235 heart cancer Diseases 0.000 abstract 1
- 208000024348 heart neoplasm Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37307202P | 2002-04-16 | 2002-04-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG164279A1 true SG164279A1 (en) | 2010-09-29 |
Family
ID=29250954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG200607217-7A SG164279A1 (en) | 2002-04-16 | 2003-04-14 | Tricyclic thrombin receptor antagonists |
Country Status (33)
Families Citing this family (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6346510B1 (en) | 1995-10-23 | 2002-02-12 | The Children's Medical Center Corporation | Therapeutic antiangiogenic endostatin compositions |
| US20040192753A1 (en) * | 2000-06-15 | 2004-09-30 | Samuel Chackalamannil | Methods of use of thrombin receptor antagonists |
| US7488742B2 (en) * | 2000-06-15 | 2009-02-10 | Schering Corporation | Thrombin receptor antagonists |
| US7235567B2 (en) * | 2000-06-15 | 2007-06-26 | Schering Corporation | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
| DE602005009355D1 (de) * | 2004-05-28 | 2008-10-09 | Schering Corp | Gehinderte himbacinanaloga als thrombinrezeptorantagonisten |
| CA2582353A1 (en) * | 2004-10-06 | 2006-04-20 | University Of Rochester | Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway |
| EP1848705B1 (en) | 2005-01-14 | 2010-02-24 | Schering Corporation | Exo- and diastereo- selective syntheses of himbacine analogs |
| CN101137614A (zh) * | 2005-01-14 | 2008-03-05 | 先灵公司 | 喜巴辛类似物的手性炔丙醇和酯中间体的制备 |
| US7772276B2 (en) * | 2005-01-14 | 2010-08-10 | Schering Corporation | Exo-selective synthesis of himbacine analogs |
| US7541471B2 (en) * | 2005-01-14 | 2009-06-02 | Schering Corporation | Synthesis of himbacine analogs |
| PT1853592E (pt) * | 2005-01-14 | 2011-05-10 | Schering Corp | S?ntese de an?logos da himbacina |
| AU2006230292A1 (en) | 2005-03-31 | 2006-10-05 | Schering Corporation | Spirocyclic thrombin receptor antagonists |
| US20070219154A1 (en) * | 2005-12-20 | 2007-09-20 | Suxing Liu | Methods for preventing and/or treating a cell proliferative disorder |
| AU2006331583A1 (en) * | 2005-12-22 | 2007-07-05 | Schering Corporation | Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery |
| AR060354A1 (es) * | 2006-04-06 | 2008-06-11 | Schering Corp | Terapias de combinacion antagonistas receptor trombina (tra) |
| CA2650404A1 (en) * | 2006-04-13 | 2007-10-25 | Schering Corporation | Fused ring thrombin receptor antagonists |
| EP2032560B1 (en) * | 2006-06-29 | 2013-05-01 | Merck Sharp & Dohme Corp. | Substituted bicyclic and tricyclic thrombin receptor antagonists |
| TWI367112B (en) | 2006-06-30 | 2012-07-01 | Schering Corp | Immediate-release tablet formulations of a thrombin receptor antagonist |
| AR061727A1 (es) * | 2006-06-30 | 2008-09-17 | Schering Corp | Sintesis de dietil [[ 5- ( 3-fluorofenil) -piridin -2il] metil] fosfonato |
| DE102006036023A1 (de) | 2006-08-02 | 2008-02-07 | Sanofi-Aventis | Imino-imidazo-pyridinderivate mit antithrombotischer Aktivität |
| TWI343262B (en) * | 2006-09-26 | 2011-06-11 | Schering Corp | Rapidly disintegrating lyophilized oral formulations of a thrombin receptor antagonist |
| WO2008042422A2 (en) | 2006-10-04 | 2008-04-10 | Schering Corporation | Bicyclic and tricyclic derivatives as thrombin receptor antagonists |
| AU2007320029A1 (en) * | 2006-10-04 | 2008-05-22 | Schering Corporation | Thrombin receptor antagonists based on the modified tricyclic unit of himbacine |
| MX2009006873A (es) * | 2006-12-22 | 2009-07-03 | Schering Corp | Promotores de desintegracion en formulaciones de granulacion humeda de dosis solida. |
| BRPI0809095A2 (pt) * | 2007-03-23 | 2014-09-09 | Schering Corp | Redução de eventos adversos após intervenção percutânea através de uso de um antagonista de receptor de trombina |
| WO2009097970A1 (de) | 2008-02-05 | 2009-08-13 | Sanofi-Aventis | Triazolopyridazine als par1-inhibitoren, ihre herstellung und verwendung als arzneimittel |
| AU2009211888B2 (en) | 2008-02-05 | 2013-06-20 | Sanofi | Triazolium salts as PAR1 inhibitors, production thereof, and use as medicaments |
| WO2009124103A2 (en) * | 2008-04-02 | 2009-10-08 | Schering Corporation | Combination therapies comprising par1 antagonists with par4 antagonists |
| WO2009143039A2 (en) | 2008-05-19 | 2009-11-26 | Schering Corporation | Heterocyclic compounds as factor ixa inhibitors |
| MX2011012861A (es) | 2009-06-04 | 2012-01-25 | Schering Corp | Metabolito activo de un antagonista de receptor de trombina. |
| WO2010144339A2 (en) | 2009-06-08 | 2010-12-16 | Schering Corporation | A thrombin receptor antagonist and clopidogrel fixed dose tablet |
| WO2011017296A1 (en) | 2009-08-04 | 2011-02-10 | Schering Corporation | 4, 5, 6-trisubstituted pyrimidine derivatives as factor ixa inhibitors |
| WO2011128421A1 (de) | 2010-04-16 | 2011-10-20 | Sanofi | Trizyklische pyridyl-vinyl-pyrrole als par1-inhibitoren |
| ES2527535T3 (es) | 2010-04-16 | 2015-01-26 | Sanofi | Piridil-vinil-pirazolo-quinolinas como inhibidores de PAR1 |
| KR101303348B1 (ko) | 2010-06-25 | 2013-09-03 | 한국화학연구원 | 트롬빈 수용체 길항제인 ［6＋5］접합 바이사이클, 그의 제조방법 및 그를 포함하는 약제학적 조성물 |
| EP2822557B1 (en) | 2012-03-06 | 2017-08-23 | Merck Sharp & Dohme Corp. | Preparation and use of bicyclic himbacine derivatives as par-receptor antagonists |
| US9604971B2 (en) | 2013-07-22 | 2017-03-28 | Aralez Pharmaceuticals Trading Dac | Co-crystal of the PAR-1 receptor antagonists vorapaxar and aspirin |
| US9808473B2 (en) | 2013-08-22 | 2017-11-07 | Merck Sharp & Dohme Corp. | Preparation and use of 3-pyridyl substituted-6,6-difluoro bicyclic himbacine derivatives as par-1 receptor antagonists |
| WO2015026693A1 (en) * | 2013-08-22 | 2015-02-26 | Merck Sharp & Dohme Corp. | 7a-amide substituted-6,6-difluoro bicyclic himbacine derivatives |
| EP3035930A4 (en) * | 2013-08-22 | 2017-03-08 | Merck Sharp & Dohme Corp. | 7a-heterocycle substituted- 6, 6-difluoro bicyclic himbacine derivatives |
| FR3014693B1 (fr) | 2013-12-16 | 2016-01-08 | Pf Medicament | Utilisation de la 3-(2-chloro-phenyl)-1-[4-(4-fluoro-benzyl)-piperazin-1-yl]-propenone pour la prevention et/ou le traitement des pathologies fonctionnelles pelvi-perineales |
| US9969724B2 (en) | 2014-04-16 | 2018-05-15 | Merck Sharp & Dohme Corp. | Factor IXa inhibitors |
| DE102014108210A1 (de) | 2014-06-11 | 2015-12-17 | Dietrich Gulba | Rodentizid |
| CN105985303B (zh) * | 2015-02-13 | 2020-08-14 | 上海彩迩文生化科技有限公司 | 抗凝血剂的制备方法、中间体及其制备方法 |
| CN106478608A (zh) * | 2015-09-01 | 2017-03-08 | 博瑞生物医药（苏州）股份有限公司 | 沃拉帕沙的硫酸盐的结晶多晶型物 |
| CN106749201A (zh) * | 2015-11-25 | 2017-05-31 | 博瑞生物医药（苏州）股份有限公司 | 一种沃拉帕沙及其中间体的制备方法 |
| WO2017134200A1 (en) * | 2016-02-05 | 2017-08-10 | Sanovel Ilac Sanayi Ve Ticaret A.S. | A novel pharmaceutical composition of vorapaxar and metoprolol |
| TR201601548A2 (tr) * | 2016-02-05 | 2018-03-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Vorapaksar ve metoprololün bi̇r farmasöti̇k kompozi̇syonu |
| TW201738221A (zh) * | 2016-04-22 | 2017-11-01 | Jiangsu Tasly Diyi Pharmaceutical Co Ltd | 新的喜巴辛類似物、其藥物組合物及其在醫藥中的應用 |
| CN106236779A (zh) * | 2016-08-22 | 2016-12-21 | 孔五 | 一种脐带血富血小板血浆prp的制备方法 |
| FR3090317B1 (fr) | 2018-12-19 | 2021-05-07 | Cvasthera | Utilisation d’un antagoniste de par-1 pour le traitement d’une maladie inflammatoire chronique intestinale |
| CN110407819B (zh) * | 2019-08-02 | 2020-06-26 | 牡丹江医学院 | 一种作为预防外科手术并发症的凝血酶受体拮抗剂 |
| US20210113536A1 (en) * | 2019-10-21 | 2021-04-22 | United States Government as Represented by the Department of Veteran Affairs | Methods and compositions for detecting and treating venous thromboembolism |
| FR3109089B1 (fr) | 2020-04-08 | 2023-04-14 | Cvasthera | Composition pharmaceutique pour le traitement des maladies inflammatoires intestinales |
| CN116133660B (zh) | 2020-07-22 | 2025-05-02 | 詹森药业有限公司 | 可用作因子XIa抑制剂的化合物 |
| US11814364B2 (en) | 2021-03-18 | 2023-11-14 | Janssen Pharmaceutica Nv | Pyridine N-oxide derivatives useful as factor XIa inhibitors |
| US11845748B2 (en) | 2021-03-18 | 2023-12-19 | Janssen Pharmaceutica Nv | Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors |
| US11919881B2 (en) | 2021-03-18 | 2024-03-05 | Janssen Pharmaceutica Nv | Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors |
| EP4070658A1 (de) | 2021-04-06 | 2022-10-12 | BIORoxx GmbH | Verwendung von blutgerinnungshemmenden verbindungen als rodentizide |
| US11897880B2 (en) | 2021-04-30 | 2024-02-13 | Janssen Pharmaceutica Nv | 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors |
| US12286429B2 (en) | 2021-07-22 | 2025-04-29 | Janssen Pharmaceutica Nv | 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives useful as a factor XIa inhibitors |
| US11958856B2 (en) | 2021-07-22 | 2024-04-16 | Janssen Pharmaceutica Nv | Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors |
| FR3134314A1 (fr) | 2022-04-08 | 2023-10-13 | Cvasthera | Composition pharmaceutique à base de vorapaxar et son utilisation pour le traitement des maladies inflammatoires intestinales |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6063847A (en) * | 1997-11-25 | 2000-05-16 | Schering Corporation | Thrombin receptor antagonists |
| WO2001096330A2 (en) * | 2000-06-15 | 2001-12-20 | Schering Corporation | Thrombin receptor antagonists |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2623810B2 (fr) | 1987-02-17 | 1992-01-24 | Sanofi Sa | Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant |
| TW197435B (enExample) * | 1990-11-22 | 1993-01-01 | Takeda Pharm Industry Co Ltd | |
| GB9102862D0 (en) * | 1991-02-11 | 1991-03-27 | Erba Carlo Spa | N-imidazolyl derivatives of substituted or alkoxymino tetrahydronaphthalenes and chromans |
| IL106197A (en) | 1992-07-30 | 1999-11-30 | Cor Therapeutics Inc | Agagonists for the rhombin receptors and pharmaceutical preparations containing them |
| US5576328A (en) | 1994-01-31 | 1996-11-19 | Elf Sanofi | Method for the secondary prevention of ischemic events |
| TR200001480T2 (tr) * | 1997-11-25 | 2000-09-21 | Schering Corporation | Trombin reseptör antagonistleri |
| FR2779726B1 (fr) | 1998-06-15 | 2001-05-18 | Sanofi Sa | Forme polymorphe de l'hydrogenosulfate de clopidogrel |
| US7488742B2 (en) * | 2000-06-15 | 2009-02-10 | Schering Corporation | Thrombin receptor antagonists |
| US20040192753A1 (en) * | 2000-06-15 | 2004-09-30 | Samuel Chackalamannil | Methods of use of thrombin receptor antagonists |
| MXPA04003610A (es) | 2001-10-18 | 2004-07-27 | Schering Corp | Analogos de himbacina como antagonistas del receptor de trombina. |
-
2003
- 2003-04-14 AT AT03718393T patent/ATE378330T1/de active
- 2003-04-14 ES ES07016461T patent/ES2338171T3/es not_active Expired - Lifetime
- 2003-04-14 WO PCT/US2003/011510 patent/WO2003089428A1/en not_active Ceased
- 2003-04-14 NZ NZ575139A patent/NZ575139A/en not_active IP Right Cessation
- 2003-04-14 EP EP07016461A patent/EP1860106B1/en not_active Expired - Lifetime
- 2003-04-14 DE DE60317493.0T patent/DE60317493T3/de not_active Expired - Lifetime
- 2003-04-14 AT AT09150995T patent/ATE494284T1/de active
- 2003-04-14 CN CN038131129A patent/CN1659162B/zh not_active Expired - Fee Related
- 2003-04-14 KR KR1020047016409A patent/KR101026929B1/ko not_active Expired - Fee Related
- 2003-04-14 AT AT07016461T patent/ATE455774T1/de not_active IP Right Cessation
- 2003-04-14 RU RU2004133375/04A patent/RU2329264C9/ru active
- 2003-04-14 PL PL373332A patent/PL214718B1/pl unknown
- 2003-04-14 DK DK03718393T patent/DK1495018T3/da active
- 2003-04-14 ES ES03718393T patent/ES2297150T7/es active Active
- 2003-04-14 DE DE60331114T patent/DE60331114D1/de not_active Expired - Lifetime
- 2003-04-14 NZ NZ535880A patent/NZ535880A/en not_active IP Right Cessation
- 2003-04-14 MY MYPI20031400A patent/MY144040A/en unknown
- 2003-04-14 DK DK09150995.0T patent/DK2065384T3/da active
- 2003-04-14 CA CA2482858A patent/CA2482858C/en not_active Expired - Lifetime
- 2003-04-14 PT PT09150995T patent/PT2065384E/pt unknown
- 2003-04-14 EP EP03718393A patent/EP1495018B3/en not_active Expired - Lifetime
- 2003-04-14 SI SI200331969T patent/SI2065384T1/sl unknown
- 2003-04-14 JP JP2003586149A patent/JP4558331B2/ja not_active Expired - Fee Related
- 2003-04-14 MX MXPA04010308A patent/MXPA04010308A/es active IP Right Grant
- 2003-04-14 SG SG200607217-7A patent/SG164279A1/en unknown
- 2003-04-14 US US10/412,982 patent/US7304078B2/en active Active
- 2003-04-14 PT PT03718393T patent/PT1495018E/pt unknown
- 2003-04-14 AU AU2003221932A patent/AU2003221932B2/en not_active Ceased
- 2003-04-14 ES ES09150995T patent/ES2357876T3/es not_active Expired - Lifetime
- 2003-04-14 PE PE2003000375A patent/PE20040412A1/es active IP Right Grant
- 2003-04-14 EP EP09150996A patent/EP2062890B1/en not_active Expired - Lifetime
- 2003-04-14 AR ARP030101302A patent/AR039570A1/es active IP Right Grant
- 2003-04-14 BR BRPI0309309A patent/BRPI0309309B8/pt not_active IP Right Cessation
- 2003-04-14 EP EP09150995A patent/EP2065384B1/en not_active Expired - Lifetime
- 2003-04-14 EP EP08012015A patent/EP1982984B1/en not_active Expired - Lifetime
- 2003-04-14 DE DE60335679T patent/DE60335679D1/de not_active Expired - Lifetime
- 2003-04-14 SI SI200331110T patent/SI1495018T1/sl unknown
- 2003-04-15 TW TW092108648A patent/TWI343919B/zh not_active IP Right Cessation
-
2004
- 2004-10-14 IL IL164585A patent/IL164585A/en active IP Right Grant
- 2004-10-14 ZA ZA200408342A patent/ZA200408342B/xx unknown
- 2004-10-15 EC EC2004005368A patent/ECSP045368A/es unknown
- 2004-11-15 NO NO20044963A patent/NO330500B1/no not_active IP Right Cessation
-
2007
- 2007-04-10 US US11/733,635 patent/US7713999B2/en not_active Expired - Lifetime
- 2007-07-06 US US11/774,358 patent/US20070270439A1/en not_active Abandoned
-
2008
- 2008-02-07 CY CY20081100152T patent/CY1107184T1/el unknown
- 2008-02-21 RU RU2008106401/04A patent/RU2008106401A/ru not_active Application Discontinuation
-
2010
- 2010-03-05 JP JP2010049903A patent/JP2010132710A/ja not_active Withdrawn
-
2011
- 2011-03-30 CY CY20111100338T patent/CY1111363T1/el unknown
-
2015
- 2015-06-29 LU LU92759C patent/LU92759I2/xx unknown
- 2015-06-29 NL NL300746C patent/NL300746I1/nl unknown
- 2015-07-01 LT LTPA2015027C patent/LTC1495018I2/lt unknown
- 2015-07-03 FR FR15C0047C patent/FR15C0047I2/fr active Active
- 2015-07-09 NO NO2015016C patent/NO2015016I1/no not_active IP Right Cessation
- 2015-07-10 CY CY2015029C patent/CY2015029I1/el unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6063847A (en) * | 1997-11-25 | 2000-05-16 | Schering Corporation | Thrombin receptor antagonists |
| WO2001096330A2 (en) * | 2000-06-15 | 2001-12-20 | Schering Corporation | Thrombin receptor antagonists |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG164279A1 (en) | Tricyclic thrombin receptor antagonists | |
| MX2009003761A (es) | Derivados biciclicos y triciclicos como antagonistas del receptor de trombina. | |
| MY139335A (en) | Substituted tricyclic himbacine derivatives that are useful as thrombin receptor antagonists | |
| WO2006105217A3 (en) | Spirocyclic thrombin receptor antagonists | |
| WO2007126771A3 (en) | Monocyclic and bicyclic himbacine derivatives useful as thrombin receptor antagonists | |
| TW200626584A (en) | Thrombin receptor antagonists | |
| GB9914486D0 (en) | Medicaments | |
| NO20062239L (no) | Nye tetrahydrospiro[piperidin-2,7'-pyrrolo[3,2-b]pyridinderivater og nye indolderivater nyttige i behandlingen av 5-HT6 reseptorrelaterte forstyrrelser | |
| WO2004012759A3 (de) | Erythropoetin zur stimulation endothelialer voläuferzellen | |
| PE20041076A1 (es) | Nuevas pirazolopirimidinas como inhibidores de la quinasa dependientes de ciclina | |
| TW200635897A (en) | Piperidine derivatives and their use as anti-inflammatory agents | |
| BRPI0418939A (pt) | derivados de nicotinamida e sua utilização como agentes terapêuticos | |
| TW200509910A (en) | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | |
| WO2007044085A3 (en) | Heteroaryl compounds and their uses as therapeutic agents | |
| WO2006044362A3 (en) | N-sulfonylpiperidine cannabinoid receptor 1 antagonists | |
| EA200701324A1 (ru) | Соединения пиридина для лечения заболеваний, опосредованных действием простагландина | |
| WO2007044885A3 (en) | Piperidine derivatives and methods of use | |
| MY140887A (en) | Thrombin receptor antagonists | |
| WO1999026932A8 (en) | By amidino group substituted heterocyclic derivatives and their use as anticoagulants | |
| MX2009003758A (es) | Antagonistas del receptor de trombina basados en la unidad triciclica modificada de himbacina. | |
| ATE342264T1 (de) | Indolderivate und deren verwendung als gnrh antagonisten | |
| DK0733051T3 (da) | Bicykliske, heterocykliske forbindelser som neurokinin A-antagonister | |
| MX2007006387A (es) | Derivados de piridina 3-substituidos como antagonistas h3. | |
| WO2007075809A3 (en) | Oxazoloisoquinoline derivatives as thrombin receptor antagonists | |
| WO2006125194A3 (en) | Piperazine derivatives and their uses as therapeutic agents |